New drug cocktail aims to boost stem cell harvest in myeloma patients
NCT ID NCT03909412
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of drugs (carfilzomib, cyclophosphamide, dexamethasone, and G-CSF) to see if it can safely and effectively collect stem cells for transplant in people with multiple myeloma. The goal is to find the best dose of carfilzomib that causes the fewest side effects while still working well. About 18 participants will be enrolled to help determine safety and the maximum tolerated dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack Meridian Health - John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact